The U.S. Food and Drug Administration has approved Tecentriq (atezolizumab) for the treatment of alveolar soft part sarcoma (ASPS) in patients 2 years and older whose tumors cannot be removed by surgery or have spread to other parts of the body. ASPS is a rare, slow-growing soft tissue sarcoma that mainly affects adolescents and young adults. Until now, there was no FDA-approved therapy specifically for this disease.
Tecentriq is a type of immunotherapy that helps the immune system recognize and attack cancer cells. The approval is based on a clinical trial that showed the drug shrank tumors in some patients. This is the first time the FDA has approved a treatment specifically for ASPS, giving patients and doctors a new option.
However, this approval does not mean Tecentriq works for everyone. Not all patients will respond, and side effects can occur. It is important for patients to talk with their doctor about whether this treatment is right for their specific situation. The drug is given as an infusion into a vein, usually every few weeks.
If you or a loved one has ASPS, discuss this new option with your healthcare team. They can help you understand the potential benefits and risks based on your individual health needs.